7B: Drug Delivery SIG 4: Precision Nanomedicine for Cancer and Inflammatory Disease

Date: Saturday, March 28, 2026
Time: 8:00 AM to 10:00 AM
Room: Centennial I

Description

This session will survey the diverse range of contemporary drug delivery systems and innovations. Drug delivering biomaterials can include nanoparticles, hydrogels, nanofibers, cell and virus-derived particles, or bioconjugates. Payloads can include DNA, RNA, antibodies, recombinant proteins, or small molecules. Disease applications can range from neurodegeneration to autoimmune disease, trauma, infection, or cancer. Work at all scales, from basic formulation science through therapeutic application in disease models is welcome. Studies that critically evaluate the impact of injection route on treatment efficacy and/or use novel imaging modalities to evaluate drug delivery performance are especially encouraged.

Moderators:

John Clegg
Assistant Professor
Gallogly College of Engineering
Peggy and Charles Stephenson
School of Biomeical Engineering
The University of Oklahoma

Cynthia Okafor
The University of Iowa | Office of Innovation

Aliasger Salem, Ph.D
Lyle and Sharon Bighley Endowed Chair & Professor / Associate Vice President for Research
University of Iowa | College of Pharmacy

  • 8:00 AM. 348. A sphingolipid-derived paclitaxel nanovesicle enhances efficacy of combination therapies in triple-negative breast cancer and pancreatic cancer.Jianqin Lu1 1University of arizona

  • 8:15 AM. 349. Engineering Dendrimer Based Platform for PSMA Mediated Drug Delivery of Sorafenib to Prostate Cancer.Ritama Ghosh, WSU ID 118999071, Anunay J Pulukuri1, Rishi Sharma1, Anjali Sharma1 1Washington State University

  • 8:30 AM. 350. Nanoparticle-based dual-drug delivery to BRAF V600E Melanoma.Ramkrishna Sen, PhD1, Mohammad Alnatour, PhD1, L.S.L Janardhanam, PhD1, Md Meraj Anjum, PhD1, Sean M Geary, PhD1, Aliasger Salem, PhD1 1University of Iowa

  • 8:45 AM. 351. Synergistic In Vivo Therapy Using Bioengineered microRNA and Chemotherapy for High-Risk Neuroblastoma.Yu-Rim Ahn, Ph.D.1, Yunyoung Lee, Ph.D.2, Toola Alkhazal, B.S.2, Kathleen Doyle, M.D.2, Meijuan Tu, Ph.D.2, Aming Yu, Ph.D.3, Jinhwan Kim, Ph.D.2, Erin Brown, M.D.2 1Organization* UC Davis Health, University of California, Davis, 2UC Davis Health, University of California, Davis, 3UC Davis Health,University of California, Davis

  • 9:00 AM. 352. Imageable Beads for Targeted Multi-Drug Delivery in Prostate Cancer Chemoembolization.Fatema Jamali, PhD1, Samuel Stealey, PhD1, Hanieh Shokrani, PhD1, Silviya Zustiak, PhD1 1Saint Louis University

  • 9:15 AM. 353. A Long-acting Injectable Nanoparticle System for Sustained Anti-TNF-α Antibody Therapy for Treatment of Ulcerative Colitis.Yicheng Zhang, PhD1, Ling Li, MD PhD2, Jiayuan Kong, PhD1, Yuanmuhuang Long, BS1, Sachin Kammula, BS1, Xiaoya Lu, MS1, Florin Selaru, MD MBA2, Hai-Quan Mao, PhD1 1Johns Hopkins University, 2Johns Hopkins University School of Medicine

  • 9:30 AM. 354. Prebiotic-Trained Gut Postbiotics Reprogram Immunity and Metabolic Homeostasis in Obesity.Dong Kwang Min1 1Sungkyunkwan University

  • 9:45 AM. 355. Drug Repositioning Using Insoluble Fibrinogen.Jun Adan-Kubo, Ph.D., MBA1 1Japan Blood Products Organization